JP5799117B2 - ウラシル誘導体からなる医薬 - Google Patents
ウラシル誘導体からなる医薬 Download PDFInfo
- Publication number
- JP5799117B2 JP5799117B2 JP2014019893A JP2014019893A JP5799117B2 JP 5799117 B2 JP5799117 B2 JP 5799117B2 JP 2014019893 A JP2014019893 A JP 2014019893A JP 2014019893 A JP2014019893 A JP 2014019893A JP 5799117 B2 JP5799117 B2 JP 5799117B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydroxyl group
- substituted
- halogen atom
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(N(C(N(*)C1=O)=O)[Al]I)=C1I[Al]* Chemical compound *C(N(C(N(*)C1=O)=O)[Al]I)=C1I[Al]* 0.000 description 18
- OLJDRPFLGATJBA-UHFFFAOYSA-N BC(CCC1)CC1C(F)(F)F Chemical compound BC(CCC1)CC1C(F)(F)F OLJDRPFLGATJBA-UHFFFAOYSA-N 0.000 description 1
- XQXKFYVGSOYETG-UHFFFAOYSA-N Bc1c(C(C(N(C)C2O)=O)=C(C)N2c2cc(C(F)(F)F)ccc2)[n](-c(cc2)ccc2C#N)nc1 Chemical compound Bc1c(C(C(N(C)C2O)=O)=C(C)N2c2cc(C(F)(F)F)ccc2)[n](-c(cc2)ccc2C#N)nc1 XQXKFYVGSOYETG-UHFFFAOYSA-N 0.000 description 1
- MQVFNDBGNKKCHV-UHFFFAOYSA-N CC(N(C[N+]1(CCCCCNC=O)[O-])c2cccc(C(F)(F)F)c2)=C(C2=CCN(C)N2c(cc2)ccc2C#N)C1=O Chemical compound CC(N(C[N+]1(CCCCCNC=O)[O-])c2cccc(C(F)(F)F)c2)=C(C2=CCN(C)N2c(cc2)ccc2C#N)C1=O MQVFNDBGNKKCHV-UHFFFAOYSA-N 0.000 description 1
- SVHGEXUZCOVFSU-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(C2=CC=[N+]2c(cc2)ccc2C#N)C1=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(C2=CC=[N+]2c(cc2)ccc2C#N)C1=O SVHGEXUZCOVFSU-UHFFFAOYSA-N 0.000 description 1
- UCXYAXJGCXLALZ-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(c([n](-c(cc2)ccc2C#N)nc2)c2I)C1=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(c([n](-c(cc2)ccc2C#N)nc2)c2I)C1=O UCXYAXJGCXLALZ-UHFFFAOYSA-N 0.000 description 1
- FQIPRFIMAYKOLN-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(c([n](-c(cc2)ccc2C#N)nc2)c2SC)C1=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N1C)=O)=C(c([n](-c(cc2)ccc2C#N)nc2)c2SC)C1=O FQIPRFIMAYKOLN-UHFFFAOYSA-N 0.000 description 1
- FJALZKZRQKYWHZ-UHFFFAOYSA-N CC(OCCNC(Nc1cc(C(F)(F)F)ccc1)=O)=O Chemical compound CC(OCCNC(Nc1cc(C(F)(F)F)ccc1)=O)=O FJALZKZRQKYWHZ-UHFFFAOYSA-N 0.000 description 1
- YFBMHULAQHMNRJ-UHFFFAOYSA-N CCCCC(NS(c1c(C(C(N2C)=O)=C(C)N(c3cc(C(F)(F)F)ccc3)C2=O)[n](-c(cc2)ccc2C#N)nc1)(=O)=O)=O Chemical compound CCCCC(NS(c1c(C(C(N2C)=O)=C(C)N(c3cc(C(F)(F)F)ccc3)C2=O)[n](-c(cc2)ccc2C#N)nc1)(=O)=O)=O YFBMHULAQHMNRJ-UHFFFAOYSA-N 0.000 description 1
- OJIHEMCXWUJENI-UHFFFAOYSA-N CCN(C(C(N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound CCN(C(C(N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O OJIHEMCXWUJENI-UHFFFAOYSA-N 0.000 description 1
- VTNZDNFHRRUSEK-UHFFFAOYSA-N CCN(C(C(NC(CCOC)=O)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound CCN(C(C(NC(CCOC)=O)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O VTNZDNFHRRUSEK-UHFFFAOYSA-N 0.000 description 1
- DLBWRYLAVWHTKZ-UHFFFAOYSA-N CCN(C(C(c([n](-c(c(F)c1)ccc1C#N)nc1)c1C(O)=O)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound CCN(C(C(c([n](-c(c(F)c1)ccc1C#N)nc1)c1C(O)=O)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O DLBWRYLAVWHTKZ-UHFFFAOYSA-N 0.000 description 1
- VKOFTLCCRFTOFN-UHFFFAOYSA-N CCN(C(C(c1c(C2(CCC2)N)cn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound CCN(C(C(c1c(C2(CCC2)N)cn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O VKOFTLCCRFTOFN-UHFFFAOYSA-N 0.000 description 1
- DIDNJRFBULFRSU-WJTDDFOZSA-N CN(C)C/C(/N(C=O)c1cc(C(F)(F)F)ccc1)=C(/C[NH+](C)[O-])\C1=CCN(C)N1c(cc1)ccc1C#N Chemical compound CN(C)C/C(/N(C=O)c1cc(C(F)(F)F)ccc1)=C(/C[NH+](C)[O-])\C1=CCN(C)N1c(cc1)ccc1C#N DIDNJRFBULFRSU-WJTDDFOZSA-N 0.000 description 1
- PWHUPBAEUBLADG-UHFFFAOYSA-N COC(CCN1)NC1OC Chemical compound COC(CCN1)NC1OC PWHUPBAEUBLADG-UHFFFAOYSA-N 0.000 description 1
- KKTLMCMQYBAOJS-OAHLLOKOSA-N C[C@H](C(O)=O)N(C(C(c1ccn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound C[C@H](C(O)=O)N(C(C(c1ccn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O KKTLMCMQYBAOJS-OAHLLOKOSA-N 0.000 description 1
- GEUAKZQPQRBJNL-OAHLLOKOSA-N C[C@H](CO)N(C(C(c1ccn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O Chemical compound C[C@H](CO)N(C(C(c1ccn[n]1-c(cc1)ccc1C#N)=C(C)N1c2cc(C(F)(F)F)ccc2)=O)C1=O GEUAKZQPQRBJNL-OAHLLOKOSA-N 0.000 description 1
- SJVCDPBDMSCOGO-UHFFFAOYSA-N N=CCC1OCCO1 Chemical compound N=CCC1OCCO1 SJVCDPBDMSCOGO-UHFFFAOYSA-N 0.000 description 1
- SYLNFMRHPUTWMH-DJWKRKHSSA-N NC(N(/C=C\C=O)c1cccc(C(F)(F)F)c1)=O Chemical compound NC(N(/C=C\C=O)c1cccc(C(F)(F)F)c1)=O SYLNFMRHPUTWMH-DJWKRKHSSA-N 0.000 description 1
- ADHSZWOYZPUNQI-UHFFFAOYSA-N OCCNC(Nc1cc(C(F)(F)F)ccc1)=O Chemical compound OCCNC(Nc1cc(C(F)(F)F)ccc1)=O ADHSZWOYZPUNQI-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019893A JP5799117B2 (ja) | 2013-02-05 | 2014-02-05 | ウラシル誘導体からなる医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013020426 | 2013-02-05 | ||
| JP2013020426 | 2013-02-05 | ||
| JP2014019893A JP5799117B2 (ja) | 2013-02-05 | 2014-02-05 | ウラシル誘導体からなる医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014169285A JP2014169285A (ja) | 2014-09-18 |
| JP2014169285A5 JP2014169285A5 (https=) | 2015-04-30 |
| JP5799117B2 true JP5799117B2 (ja) | 2015-10-21 |
Family
ID=51691962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014019893A Expired - Fee Related JP5799117B2 (ja) | 2013-02-05 | 2014-02-05 | ウラシル誘導体からなる医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5799117B2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| US12612368B2 (en) | 2020-11-06 | 2026-04-28 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9802919B1 (en) * | 2016-05-31 | 2017-10-31 | Chiesi Farmaceutici S.P.A. | Compounds |
| KR20190015492A (ko) * | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| GB201918414D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency |
| EP3945091B1 (en) * | 2020-07-31 | 2024-01-03 | Abarceo AB | Novel vdac1 inhibitors |
| WO2023033097A1 (ja) * | 2021-09-02 | 2023-03-09 | Ｅａファーマ株式会社 | 複素環スルホンアミド誘導体の製造方法、およびその合成中間体 |
| CN113952359A (zh) * | 2021-11-19 | 2022-01-21 | 大连理工大学盘锦产业技术研究院 | 顺铂与Tri-1的联合抗肺癌药物组合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| CN104024241B (zh) * | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
-
2014
- 2014-02-05 JP JP2014019893A patent/JP5799117B2/ja not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| US12612368B2 (en) | 2020-11-06 | 2026-04-28 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014169285A (ja) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5709999B2 (ja) | ウラシル誘導体およびその医薬用途 | |
| JP7482918B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| JP5799117B2 (ja) | ウラシル誘導体からなる医薬 | |
| ES2615238T3 (es) | Derivados de tetrahidroquinolinas como inhibidores de bromodominio | |
| EP2718279B1 (en) | Novel compounds as modulators of gpr-119 | |
| US7994331B2 (en) | Heterocycle-substituted benzimidazole derivative | |
| JP5518887B2 (ja) | 四置換ピリダジンヘッジホッグ経路アンタゴニスト | |
| WO2012162254A1 (en) | Inhibitors of lrrk2 kinase activity | |
| HK1217482A1 (en) | Enzyme modulators and therapies | |
| EA019723B1 (ru) | ИНГИБИТОРЫ cMET | |
| JP6855636B2 (ja) | イミダゾリジン化合物 | |
| WO2012002502A1 (ja) | ジヒドロピリミジノン誘導体およびその医薬用途 | |
| EP2934536B1 (en) | FACTOR IXa INHIBITORS | |
| EP1762568A1 (en) | Pyrazole derivatives | |
| US7807690B2 (en) | 2,3-dihydro-iminoisoindole derivatives | |
| WO2005080392A1 (ja) | ピラゾロキノロン誘導体およびその用途 | |
| CN114867719B (zh) | 吡咯烷和哌啶化合物 | |
| IL296632A (en) | phd inhibitory compounds, compositions and use | |
| HK1197675A (en) | Uracil derivative and use thereof for medical purposes | |
| HK40000783B (zh) | 化合物及其用於降低尿酸水平的用途 | |
| HK1196611B (en) | Novel compounds as modulators of gpr-119 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150128 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150512 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150630 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150804 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150824 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5799117 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| LAPS | Cancellation because of no payment of annual fees |